Although the biomarkers show reasonable accuracy to discriminate controls from AD patients as well as prodromal AD in MCI patients [12–15], it has been shown in population-based studies that healthy elderly people who later develop AD have reductions in CSF Aβ42 levels while tau levels are normal [16, 17]. Here, MAPT is linked to Alzheimer disease.